Dharmarajan Hariharan specializes in antitrust economics, empirical methods, and applied econometrics. Dr. Hariharan has conducted economic analysis for investigations and cases involving a variety of industries such as healthcare service providers and insurers, telecom/television, cement, airlines, high-technology semiconductors, and natural gas. Dr. Hariharan has worked on issues relating to market power and competition in the healthcare sector, among others, and has experience analyzing mergers, price-fixing and market allocation, and exclusionary conduct.
PhD, Economics, University of Pittsburgh
MS, Chemical Engineering, West Virginia University
BE, Chemical Engineering, Bangalore University
- Provided expert support on behalf of DOJ in its litigation effort to block the merger between AT&T and Time Warner Inc.
- On behalf of Highmark Health, provided analysis to the Pennsylvania Insurance Department (PID) requesting modifications of certain conditions in the PID’s 2013 order, which was put in place following the creation of the Allegheny Health Network (AHN) via Highmark’s affiliation with the then-failing West Penn Allegheny Health System.
- On behalf of Steward Health Care in Steward Health Care System LLC et al. v. Blue Cross & Blue Shield of Rhode Island, supported Professor Leemore Dafny in providing written and deposition testimony on monopoly power, monopsony power, and exclusionary conduct.
- On behalf of Humana in connection with its proposed merger with Aetna, supported Aetna and Humana’s efforts to respond to DOJ’s second request, and supervised analyses of likely competitive effects and barriers to entry and exit in the sale of Medicare Advantage products.
Supported testifying expert for the Department of Justice’s potential challenge of the Stamps.com/Endicia merger.
- Supported lead expert on behalf of Holcim Ltd. and Lafarge SA, two vertically integrated building materials firms who proposed a $25 billion merger that would create the world’s largest cement manufacturer.
- Supported the lead expert working on behalf of Thermo Fisher Scientific in evaluating the likely competitive effects of its proposed $13.6 billion acquisition of Life Technologies.
- Supported the economic expert working on behalf of merging hospitals, identified competitive overlaps, assessed relevant markets, analyzed likely competitive effects, and presented findings to the FTC and California State Attorney General’s Office.
- In American Airlines v. Sabre and American Airlines v. Travelport, supported the testifying expert in estimating the impact of alleged anticompetitive practices by the defendants in suppressing American bookings via multiple means.
- In AMD v. Intel, supported the testifying expert on behalf of AMD in estimating the impact of Intel’s anticompetitive practices on AMD’s profits.
- Examined potential merger outcomes in the Express Scripts–Medco merger by simulation of first- and second-price auctions.